A Randomized, Double-blind, Placebo-controlled, Adaptive-design Study to Assess the Safety and Efficacy of Daily 200 mg Fluvoxamine as add-on Therapy to Standard of Care in Moderate Severity COVID-19 Patients
January 22, 2021 | Hospital-Based |
2 x 100 mg fluvoxamine daily po. (with careful dose escalation and tapered dose reduction). Overall treatment period is 74 days.
Please check the captcha to verify you are not a robot.
IMPORTANT: To protect your privacy, your subscription will only be confirmed once you click on the confirmation link in the email just sent to you. If the email is not in your inbox, check your junk/spam folder.
Something went wrong. Please check your entries and try again.